Lockwood | AI Transformation Index

Overview

The Lockwood Group is a full-service medical communications agency that earns fee-for-service revenue by helping pharmaceutical, biotech, and medical device companies translate complex scientific and clinical data into compliant, scientifically rigorous communications — including medical strategy, expert engagement, content development, regulatory consulting, accredited medical education, and market access services — targeted at healthcare professionals and stakeholders.

Executive Summary

Lockwood is a high-AI-opportunity, moderate-durability business: it sits on a large, entirely cognitive workforce doing medical writing, scientific strategy, and education development with basic-IT sophistication and no AI program — precisely the profile where PE-sponsored AI transformation creates step-change value in staffing ratios and throughput. The risk is that the same characteristics driving the opportunity also drive the durability concern — AI doesn't just help Lockwood, it helps every competitor and threatens to shift content production in-house at pharma clients, compressing the agency margin pool over time. The accredited education acquisitions (Research To Practice, IDEOlogy Health) are the most durable part of the portfolio, anchoring a CME-credentialing moat that AI cannot easily bypass, and the strategic priority should be using AI to rapidly expand throughput in those high-credentialing-barrier services while protecting against commoditization of the core medical writing business.

Durability Rationale

Lockwood's durability is structurally challenged because its core production function — generating scientific content and medical communications — is a knowledge output that AI can increasingly replicate with high fidelity, and its intermediary position between pharma clients and HCP audiences is exposed to both client internalization and AI-native agency competition. The regulatory compliance layer (MLR processes, CME accreditation) and KOL relationship networks provide meaningful but insufficient insulation — they protect workflow gatekeeping steps rather than the underlying value proposition, and AI-augmented lean competitors can comply with the same regulations at lower cost. The accredited education acquisitions add stickiness through credentialing moats, but the core medical communications agency model operates in a moderately concentrated market with project-based contracting that reprices at renewal, giving clients leverage as AI alternatives emerge.

Opportunity Rationale

The AI opportunity for Lockwood is substantial and predominantly unrealized — the business is almost entirely cognitive labor, the engineering team has basic-IT sophistication with no visible AI initiatives, and the core production workflow (medical writing, content strategy, education development) is precisely where LLMs deliver their most dramatic compression. The magnitude of the step-change is real: staffing ratios, project turnaround times, and content variant economics could shift fundamentally with AI augmentation, and the company's lack of internal AI capability means an outside catalyst would capture meaningful value that Lockwood cannot build on its own. The domain intelligence layer adds meaningful amplification potential in the strategic and KOL engagement dimensions, though the content-production core is more rules-based than deeply judgment-driven, which moderates the ceiling on domain-specific AI advantage.

Key Risks